133 related articles for article (PubMed ID: 38252069)
21. Prediction of Early Death in Patients with Early-Stage NSCLC-Can We Select Patients without a Potential Benefit of SBRT as a Curative Treatment Approach?
Klement RJ; Belderbos J; Grills I; Werner-Wasik M; Hope A; Giuliani M; Ye H; Sonke JJ; Peulen H; Guckenberger M
J Thorac Oncol; 2016 Jul; 11(7):1132-9. PubMed ID: 27060654
[TBL] [Abstract][Full Text] [Related]
22. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
Paix A; Noel G; Falcoz PE; Levy P
Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis.
Nanda RH; Liu Y; Gillespie TW; Mikell JL; Ramalingam SS; Fernandez FG; Curran WJ; Lipscomb J; Higgins KA
Cancer; 2015 Dec; 121(23):4222-30. PubMed ID: 26348268
[TBL] [Abstract][Full Text] [Related]
25. Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry.
Yun J; Cho JH; Hong TH; Yang K; Ahn YC; Kim HK; ;
Cancer Res Treat; 2023 Oct; 55(4):1171-1180. PubMed ID: 37080606
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC.
Ackerson BG; Tong BC; Hong JC; Gu L; Chino J; Trotter JW; D'Amico TA; Torok JA; Lafata K; Chang C; Kelsey CR
Lung Cancer; 2018 Nov; 125():185-191. PubMed ID: 30429018
[TBL] [Abstract][Full Text] [Related]
27. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis.
Palma D; Visser O; Lagerwaard FJ; Belderbos J; Slotman BJ; Senan S
J Clin Oncol; 2010 Dec; 28(35):5153-9. PubMed ID: 21041709
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
Ager BJ; Wells SM; Gruhl JD; Stoddard GJ; Tao R; Kokeny KE; Hitchcock YJ
Lung Cancer; 2019 Dec; 138():6-12. PubMed ID: 31593894
[TBL] [Abstract][Full Text] [Related]
29. Patterns of Use of Stereotactic Body Radiation Therapy Compared With Surgery for Definitive Treatment of Primary Early-stage Non-small Cell Lung Cancer.
Jang JK; Atay SM; Ding L; David EA; Wightman SC; Kim AW; Ye JC
Am J Clin Oncol; 2022 Apr; 45(4):146-154. PubMed ID: 35320815
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal?
Gulstene S; Ruwanpura T; Palma D; Joseph N
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):733-740. PubMed ID: 36050221
[TBL] [Abstract][Full Text] [Related]
31. Safety-net burden hospitals and likelihood of curative-intent surgery for non-small cell lung cancer.
Virgo KS; Little AG; Fedewa SA; Chen AY; Flanders WD; Ward EM
J Am Coll Surg; 2011 Nov; 213(5):633-43. PubMed ID: 21907598
[TBL] [Abstract][Full Text] [Related]
32. Role of stereotactic body radiotherapy for early-stage non-small-cell lung cancer in patients borderline for surgery due to impaired pulmonary function.
Tomita N; Okuda K; Kita N; Niwa M; Hashimoto S; Murai T; Ishikura S; Nakanishi R; Shibamoto Y
Asia Pac J Clin Oncol; 2022 Dec; 18(6):634-641. PubMed ID: 35098662
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
34. The patient's perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC).
Shaverdian N; Wang PC; Steinberg M; Lee P
Lung Cancer; 2015 Nov; 90(2):230-3. PubMed ID: 26358313
[TBL] [Abstract][Full Text] [Related]
35. Surgery or stereotactic body radiotherapy for elderly stage I lung cancer? A propensity score matching analysis.
Miyazaki T; Yamazaki T; Nakamura D; Sato S; Yamasaki N; Tsuchiya T; Matsumoto K; Kamohara R; Hatachi G; Nagayasu T
Surg Today; 2017 Dec; 47(12):1476-1483. PubMed ID: 28447170
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer.
Yu JB; Soulos PR; Cramer LD; Decker RH; Kim AW; Gross CP
Cancer; 2015 Jul; 121(14):2341-9. PubMed ID: 25847699
[TBL] [Abstract][Full Text] [Related]
38. Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule.
Samson P; Rehman S; Juloori A; DeWees T; Roach M; Bradley J; Videtic GMM; Stephans K; Robinson C
Pract Radiat Oncol; 2018; 8(6):404-413. PubMed ID: 29907514
[TBL] [Abstract][Full Text] [Related]
39. Hospital Utilization of Stereotactic Body Radiation Therapy and Rates of Surgical Refusal.
Till BM; Whitehorn G; Mack SJ; Thosani D; Rahman U; Grenda T; Evans NR; Okusanya OT
Ann Thorac Surg; 2023 Feb; 115(2):347-354. PubMed ID: 36027934
[TBL] [Abstract][Full Text] [Related]
40. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
